Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00168194|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : January 20, 2012
It remains unclear why some individuals are able to clear HBV from their bodies while in others HBV is a persistent infection. We plan to investigate this process by collecting blood and analysing how the patient's white blood cells respond to different pieces of the HBV virus. We will use new tools that can precisely tell us which component of the immune response may be different in individuals who are chronically infected with HBV and also in individuals who are also infected with HIV.
The primary aims are therefore:
- To characterize HBV-specific T cell responses in HBV chronic carriers, and identify novel immunogenic regions in both HLA-A2+ and non-HLA-A2+ individuals.
- To determine the effect of HIV infection on HBV-specific T-cell responses
|Condition or disease|
|Hepatitis B HIV Infections|
|Study Type :||Observational|
|Actual Enrollment :||104 participants|
|Official Title:||Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History|
|Study Start Date :||December 2004|
|Actual Study Completion Date :||December 2009|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168194
|The Alfred Hospital, Commercial Road|
|Melbourne, Victoria, Australia, 3004|
|Principal Investigator:||Sharon Lewin, Professor||Burnet Institute, Melbourne|